MarketCap
Facebook
X
Telegram
Centogene N.V. Interest Expense | CNTG
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Centogene N.V.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.42 M | 4.91 M | 802 K | 1.38 M | 2.03 M | 1.08 M | 1.02 M | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 8.42 M | 802 K | 2.8 M |
Quarterly Interest Expense Centogene N.V.
| 2023-Q4 | 2023-Q2 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.42 M | 3.6 M | 4.91 M | - | - | 859 K | 802 K | 263 K | 212 K | 259 K | 1.38 M | 793 K | 269 K | 449 K | - | 1.43 M | 211 K | 220 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.42 M | 211 K | 1.6 M |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Agilent Technologies
A
|
112 M | $ 171.29 | 2.09 % | $ 48.6 B |  USA |
 |
Anixa Biosciences
ANIX
|
500 K | $ 2.95 | 6.5 % | $ 95.7 K | USA |
|
Biodesix
BDSX
|
7.72 M | $ 29.06 | 4.83 % | $ 219 M | USA |
 |
Biomerica
BMRA
|
367 | $ 2.05 | 0.84 % | $ 5.98 M | USA |
 |
BioNano Genomics
BNGO
|
5.9 M | $ 1.45 | 0.96 % | $ 7.9 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
-30 K | $ 15.83 | 0.62 % | $ 166 M |  China |
 |
Bioventus
BVS
|
-1.45 M | $ 13.52 | 2.97 % | $ 901 M | USA |
 |
CareDx, Inc
CDNA
|
524 K | $ 69.85 | 4.02 % | $ 3.72 B | USA |
 |
Celcuity
CELC
|
5.33 M | $ 73.62 | 2.11 % | $ 3.44 B | USA |
 |
Co-Diagnostics
CODX
|
106 K | $ 1.1 | 1.85 % | $ 1.46 M | USA |
 |
Charles River Laboratories International
CRL
|
-22.6 M | $ 310.77 | 7.07 % | $ 15.4 B | USA |
 |
Castle Biosciences
CSTL
|
144 K | $ 36.65 | 3.07 % | $ 1.06 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
26 M | $ 232.22 | 0.07 % | $ 25.8 B | USA |
 |
Danaher Corporation
DHR
|
-222 M | $ 221.21 | 3.34 % | $ 158 B | USA |
 |
DarioHealth Corp.
DRIO
|
-1.93 M | $ 5.8 | 1.24 % | $ 23.1 M |  Israel |
 |
DexCom
DXCM
|
177 M | $ 86.9 | 1.8 % | $ 33.9 B | USA |
 |
Fulgent Genetics
FLGT
|
153 K | $ 22.45 | 4.52 % | $ 691 M | USA |
 |
Guardant Health
GH
|
-10.5 M | $ 187.22 | 5.3 % | $ 23.5 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 168.33 | 3.88 % | $ 13.2 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
41.6 M | $ 527.07 | 1.67 % | $ 42.4 B | USA |
 |
Illumina
ILMN
|
340 M | $ 293.69 | 7.56 % | $ 45.5 B | USA |
 |
IQVIA Holdings
IQV
|
729 M | $ 266.09 | 3.05 % | $ 45.7 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
224 M | $ 308.65 | 0.05 % | $ 25.7 B | USA |
 |
Lantheus Holdings
LNTH
|
31.3 M | $ 100.19 | 0.23 % | $ 6.76 B | USA |
 |
Medpace Holdings
MEDP
|
-5.34 M | $ 620.51 | 3.51 % | $ 17.9 B | USA |
 |
Mettler-Toledo International
MTD
|
68.5 M | $ 1 541.63 | 3.73 % | $ 31.8 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
800 K | $ 4.58 | 0.88 % | $ 424 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-691 K | $ 6.31 | 4.13 % | $ 4.97 M | USA |
 |
NeoGenomics
NEO
|
296 K | $ 19.13 | 3.57 % | $ 2.45 B | USA |
 |
Neogen Corporation
NEOG
|
24.1 M | $ 13.01 | 7.08 % | $ 2.83 B | USA |
 |
National Research Corporation
NRC
|
-95 K | $ 20.78 | 2.11 % | $ 465 M | USA |
 |
Natera
NTRA
|
4.07 M | $ 425.64 | 3.73 % | $ 58.2 B | USA |
 |
OPKO Health
OPK
|
207 M | $ 1.57 | 0.64 % | $ 1.18 B | USA |
 |
Pacific Biosciences of California
PACB
|
14.8 M | $ 2.87 | 12.99 % | $ 861 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 23.91 | 0.04 % | $ 22.7 B |  Niderland |
 |
Precipio
PRPO
|
839 K | $ 24.0 | 3.76 % | $ 38.5 M | USA |
 |
Personalis
PSNL
|
205 K | $ 16.4 | 0.74 % | $ 1.46 B | USA |
 |
QIAGEN N.V.
QGEN
|
-6.65 M | $ 45.79 | 2.34 % | $ 9.95 B | Niderland |
 |
RadNet
RDNT
|
32.1 M | $ 70.63 | 1.0 % | $ 5.31 B | USA |
 |
Senseonics Holdings
SENS
|
-23 K | $ 10.31 | 4.35 % | $ 430 M | USA |
 |
Sotera Health Company
SHC
|
8.55 M | $ 18.55 | 1.81 % | $ 5.27 B | USA |
 |
Neuronetics
STIM
|
716 K | $ 2.2 | 1.85 % | $ 145 M | USA |
 |
Thermo Fisher Scientific
TMO
|
-12 M | $ 676.76 | 3.35 % | $ 255 B | USA |
 |
Twist Bioscience Corporation
TWST
|
-903 K | $ 205.0 | 8.66 % | $ 12.3 B | USA |
 |
VolitionRx Limited
VNRX
|
-1.76 M | $ 0.23 | 0.35 % | $ 28.9 M |  Singapore |
 |
Waters Corporation
WAT
|
14.3 M | $ 440.12 | 3.51 % | $ 26.2 B | USA |
 |
Exagen
XGN
|
2.34 M | $ 8.46 | 3.55 % | $ 182 M | USA |
 |
Syneos Health
SYNH
|
82.4 M | - | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |